Preliminary observations on the drug I.C.I. 50172 (4-(2-hydroxy-3-isopropylaminopropoxy) acetanilide) have shown it to block isoprenaline-induced tachycardia in the experimental animal (Barrett et al., 1968) and also in normal volunteers (Brick et al., 1968) . In this paper we report the haemodynamic effects in man of the intravenous administration of 5 mg. of I.C.I. 50172 during submaximal exercise.
Materials and Methods
Observations were made on 10 patients whose ages ranged from 19 to 60. All had been referred for an exercise test, the indication being atypical chest pain in six and a systolic murmur in the others. Two patients had trivial pulmonary stenosis, with a gradient of 10-15 mm. Hg across the valve, and one had very slight aortic incompetence. The others had no demonstrable haemodynamic abnormality.
The present investigation was performed immediately after the diagnostic exercise study. Before proceeding, the nature and purpose of the investigation was explained to the patients, and their permission was sought before the drug was administered.
Right heart pressures were measured in six patients through a fine nylon catheter, which was introduced percutaneously into an arm vein and advanced to the pulmonary artery. In the three patients with minor valve lesions a No. 8 twin-lumen catheter was introduced and a routine right heart pressure and sample run performed before the start of the study. The catheter was then positioned with its tip impacted in the pulmonary capillary wedge position. Systemic arterial pressures were recorded through Teflon tubing (internal diameter 1.1 mm., external diameter 1.6 mm. Effects of I.C.I. 50172-Gibson and Sowton following the intravenous injection of 5 mg. of I.C.I. 50172 is shown in Fig. 2 . Discussion In the present study the drug was given by rapid intravenous injection during continuous submaximal exercise rather than between twq periods of exercise. This avoided the possibility that the effects observed were due to differences that may occur between such identical exercise periods in the absence of any therapeutic intervention (Burkart et al., 1967) . The absence of any significant difference between the two sets of control values shows that a steady state had been reached before the drug was administered, and is in keeping with the results of a previous investigation from our laboratory when identical techniques were used (Sowton and Burkart, 1967) . The patients were thoroughly familiar with the apparatus at the start of the investigation, since they had all just completed a standard exercise test. Though this group of patients cannot be regarded as normal, the cardiac function was excellent in all but one case, and it seems likely that these findings are applicable to subjects without significant heart disease. Howitt (1967) Preliminary observations in dogs have demonstrated that I.C.I. 50172 has a sympathomimetic effect on the ventricular myocardium (Barrett et al., 1968) . In the present study the increased stroke volume was accompanied by a significant prolongation of the left ventricular ejection time, with the result that the mean systolic ejection rate remained unchanged. This last quantity has been shown to decrease with positive inotropic stimuli (Braunwald et al., 1958) , and the lack of any change after I.C.I. 50172 provides indirect evidence against the drug having any such effect. It therefore seems likely that the increase in stroke volume was secondary to the change in pulse rate rather than to a further effect of the drug on left ventricular function. The similarity in time course between the drop in pulse rate and the increase in stroke volume also supports this relationship. The study gives no indication of the mechanism by which the cardiac output Animal work with I.C.I. 50172 indicates that it has *..-a selective action, blocking catecholamine effects on the heart but not on the peripheral vascular tree (Barrett et al., 1968 (Epstein et a!., 1965; Sowton and Hamer, 1966 Beta-adrenergic receptor blocking agents have had wide application since they were first introduced into clinical practice (Prichard et al., 1963 ; Stock, 1966) , particularly in the treatment of angina pectoris (Prichard et al., 1963 ; Wolfson et al., 1966; Gillam and Prichard, 1966;  Hamer and Sowton, 1966) . Unfortunately these drugs have had adverse effects on myocardial function in some instances (Chamberlain, 1966; Stephen, 1966) , and this may often be due to the reduction in cardiac contractile force that they are known to produce (Shanks, 1966) .
A drug with a similar action in angina but without the deleterious effects on myocardial function would be a most valuable addition to those currently available. I.C.I. 50172 (4-(2-hydroxy-3-isopropylaminopropoxy) acetanilide) has been shown in animal experiments to have approximately 40% of the inhibitory effect of the same dose of propranolol on isoprenaline-induced tachycardia, and mobilization of free fatty acids (Barrett et al., 1968) . It has, in addition, some intrinsic sympathomimetic action not shown by propranolol (Barrett, personal communication, 1967) . Its haemodynamic effects in a group of patients with ischaemic heart disease are reported here. ,
Results were obtained from 14 male patients whose ages ranged from 36 to 67 years (mean 54.6). Five had proved myocardial infarction from one to six days previously and were being treated in the coronary care area of the National Heart Hospital. In all these patients haemodynamic monitoring was being performed in addition to the usual electrocardiographic monitoring, to provide information of immediate therapeutic value. The drug was given only when haemodynamic values had returned to the normal range. Nine subjects had typical severe angina pectoris and were being assessed for possible surgical treatment of their coronary artery disease by internal mammary artery implants. Included in this assessment was a study of cardiac function and degree of ventricular ischaemia which involved haemodynamic measurements, and the drug was given under these circumstances.
In all cases the technique of study was the same. The patients were studied in the morning after their usual breakfast and without premedication. Pulmonary artery pressure was recorded via either a fine nylon tube which was inserted percutaneously into an arm vein and guided by flow to the pulmonary artery or a No. 8 double-lumen catheter which was passed under fluoroscopic control so that the proximal lumen was in the pulmonary artery. A Teflon tube (outer diameter 1.6 mm., inner diameter 1.1 mm.) was inserted into the brachial artery percutaneously and passed to the aortic arch. Pressures were measured with Consolidated Electrodynamics straingauge transducers (type 4-326-L212) and recorded on a Sanborn (964) four-channel direct writer. Mean pressures were obtained by electrical integration. Cardiac output was measured by the dye dilution technique, 5 mg. of indocyanine green being injected into the pulmonary artery and blood withdrawn from the aorta with a Kipp and Zonen constant-rate pump through a Gilford densitometer, the output of which was fed into a Honeywell recorder. Stroke volume was obtained by dividing cardiac output by heart rate, total peripheral resistance by dividing mean aortic pressure by cardiac output, and mean systolic ejection rate by dividing stroke volume by systolic ejection time.
The above measurements were taken before and five minutes after the injection of 5, 15, or 25 mg. of I.C.I. 50172 into the pulmonary artery. Measurements were made in one patient at all three dosage levels and the others received only one dose, so that six patients were given S mg., four 15 mg., and six 25 xng.
Student's t test was used for the statistical analysis.
Results
The results for patients with infarction and for those with angina were similar and so have been considered together. The mean levels of the various values for each dosage group are given in the Table. It can b: seen that heart rate was significantly reduced in all three dosage groups. Systolic ejection time was, however, significantly prolonged only in the groups
